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Abstract Theobjectiveofthe studywastoinvestigatethepossible associationofChlamydia pneumoniae (Cpn) inacute
exacerbations of chronic obstructive pulmonary disease (COPD) patients.Thirty-eight acutely exacerbated COPD pa-
tients and17 healthy smokerswere enrolled in the study, as the study and control groups respectively.Nasopharyngeal
swabs andpaired serum samples for antibody testing of Cpn (microimmuno£uorescenceöMIF) were obtained fromall
subjects. Sputum cultures of COPD patients were also performed.No pathogenic bacteria were isolated from naso-
pharyngeal swabs in any subject. Serologic evidence of recent Cpn infection was observed in13 (34%) COPD patients
andin one (5%) control subject.Theprevalence of Cpn IgGand IgMantibodiesrepresentingacute infectionwere signi¢-
cantlyhigherin COPDpatients thanincontrol subjects (P50?05 and P50?01respectively).Prevalence of IgA antibodies
and IgG pre-existingantibodies didnot showanydi¡erence (P40?05).Microbiologic culture ofthe sputayielded poten-
tially pathogenic micro-organisms in 23 of 38 (60%) COPD patients. Alpha-haemolytic streptococcus (35%), Niesseria
spp. (31%) and Candida spp. (9?5%) weremost prominentmicro-organisms in positive cultures. Although a high preva-
lence of IgGantibodies against Cpnwasdetected, itwas the sole causative agentinonly four (10%) patients.Weconclude
that a remarkable numberof COPD patients (34%) are acutely infectedwith Cpn anditmayeither be the sole causative
agentor frequently a co-agent in acute exacerbations.c 2001Harcourt Publishers Ltd
doi:10.1053/rmed.2001.1159, available online athttp://www.idealibrary.comon
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Chlamydia pneumoniae (Cpn) is an obligate intracellular
human pathogen causing acute upper and lower respira-
tory tract infections including pharyngitis, sinusitis,
bronchitis and pneumonia. It is implicated for 5% of
bronchitis and 10^15% of community-acquired pneu-
monia (1).
Chronic obstructive pulmonary disease (COPD) is a
chronic disease with signi¢cant cost and morbidity. In
patientswithCOPD, acute recurrentbacterial infections
of the tracheobronchial tree are common and have a
negative impact on quality of life and progression of the
disease, particularly in more severely a¡ected patients.
Currentor ex-smoking, air pollution, low socioeconomic
status, recurrentrespiratory infections during childhood
and hereditary factors are well-known risk factors in
COPD patients (1^3).Received15 March 2001and accepted in revised form11June 2001
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E-mail: karnak@dialup.ankara.edu.trSmoking per se is quantitatively associated with
increased levels of Cpn serum antibodies in subjectswith
or without COPD. Smoking most probably facilitates
Cpn lung infection and/or promotes deeper penetration
of Cpn into lung tissue to produce greater antibody
response. Smoking seems to play an aetiological role in
both diseases: COPD and Cpn (1,4^6).
Recent studies have suggested the possibility of Cpn
involvement in 4^16% of COPD exacerbations of in
hospitalized or outpatients (1,2,5,6).
Therefore, we conducted a prospective study to
establish the causative micro-organisms, especially
Cpn, in acutely exacerbated and hospitalized COPD
patients.
MATERIALANDMETHODS
Study population
Study population consisted of 55 subjects: 38 COPD
patients and 17 healthy smokers (mean age: 62?5+8?2
years, range: 47^78 years,M/F: 45/10) (Table1). Informed
consentwas obtained from all subjects.
TABLE 1. Epidemiological characteristics
COPD (n= 38) Control (n=17 ) P value
Age (years) 64?5+8?2 60?5+8?3 40?05
Male/female ratio 34/4 11/6 ^
Cigarette consumption (pack-years) 37?7+14?1 30?5+8?2 40?05
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Thirty-eight COPD patients (mean age: 64?5+8?2
years, age range: 47^78 years, M/F: 34/4) were enrolled
into the study in Ankara, Turkey. All patients had an es-
tablished diagnosis of COPD, and most of them had se-
vere disease according to American Thoracic Society
(ATS) criteria (7). The patients su¡ered from increased
dyspnoea, cough and sputum production at admission.
Patients who had received antibiotics within 2 weeks or
who had acute respiratory illness within 2 months prior
to enrollment were excluded. Other exclusion criteria
were: evidence of immunosuppression, malignancy and
coagulopathy. Pulmonary function tests and arterial
blood gases were alsomeasured.
Controls
Seventeen healthy smokers served as control subjects
(mean age: 60?5+8?3 years, age range: 48^65 years,
M/F: 11/6). They had no signs or symptoms of acute re-
spiratory illness or COPD according to ATS criteria,
and their pulmonary function tests and arterial blood
gases values were normalwith regards to age.
Culture and serology
The purulence of sputum samples from COPD patients
was assessed through counts of polymorphonuclear leu-
kocytes (425) and squamous epithelial cells (510 for
per low-power ¢eld) on Gram-stain. If the sputum did
not these criteria, sampling was repeated, avoiding oral
contamination (2,8). Nasopharyngeal swab specimens
were obtained from all subjects by the attending by na-
sopharyngeal application. Swabs and sputa of COPD pa-
tients were plated on sheep blood agar (Oxoid),
chocolate agar with horse blood, eosin methylene blue
agar (Oxoid) and Sabouraud for various micro-organ-
isms. After an incubation period of 24^48h at 378C,mi-
cro-organismswere identi¢edusing standard laboratory
methods (8).
As this study was planned to detect Cpn serologically
PCR and Cpn culture could not be done.
Paired serum samples were collected at intervals of 4
weeks. All sera were stored at 7708C until testing. Amicro-immuno£uorescence (MIF) test was used for
titration of IgG, IgM and IgA antibodies against Cpn
(MRLDiagnostic IgG, IgM, IgA,U.S.A.) Bu¡ered solutions
eliminated rheumatoid factors.The lamellas obtained by
using a suitable technique were examined by a 400mm
augmented £uorescent microscope (Nikon SE400). C.
psittaci,C. trachomatis and C. pneumoniae antigens were
also studied using the same kit.
IgM1:16 or IgG1: 512, or a four-fold rise in IgGwas
considered to be signi¢cant for acute or current infec-
tion,whereas IgM51:16 and1:165IgG51:256 orpositiv-
ity was considered as chronic or pre-existing
(=previous) infection (4,9,10). IgA1:16 levels have been
reported as indicative of acute versus pre-existing infec-
tion (4). In reinfection, IgA response is often a predomi-
nant feature, often accompaniedwith an elevation of IgM
antibodies. IgA antibodies tend to disappear more
rapidly, as the half-life of IgA only 5^6 days. Elevated
IgA titresmore than1week is considered a reliable mar-
ker of chronic infection (6).
Statistics
Mean age and smoking status was compared with a stu-
dent’s t-test.Comparison of immunoglobulin prevalences
was done by a two-tailed Fischer’s exact test. Correla-
tion between age and smoking status or immunoglobulin
prevalencewereidenti¢edbyPearsoncorrelationanalysis.
Any P-value50?05 was considered signi¢cant.
RESULTS
The clinical characteristics of the COPD patients and
controls are presented inTable l.Groups were not di¡er-
ent with regard to age (P40?05). Most of the subjects
were current or ex-smokers; groups were compatible
with respect to smoking status (P40?05).
In the COPD group, a very low percentage of (PFT),
blood gas: parameters, were found, representing severe
air£ow obstruction (Table 2).
IgM prevalence of COPD patients were signi¢cantly
higher compared to controls (P50?0l). Twelve (31%)
COPD patients and only one (5?8%) control had a high
IgM antibody level, representing an acute episode of
Cpn (Table 3).
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of the controls hadhigh levels of IgG antibody (P50?05);
12 (31%) were above1: 512 titre, one (2%) had a four-fold
rise. The number of Cpn: IgG antibody positivity (from:
16 to 1: 256 titre) was 25 in total (65%) in
the COPD population whereas it was found in only
seven (41%) cases representing previous infection in con-
trols, which was not statistically di¡erent (P=0?056;
Table 3)
IgA seropositivity was not di¡erent between the
groups (P40?05). Twelve patients (31%) in the COPD
group had elevated IgA antibody either with elevated
IgMor elevated IgGantibody.However, six (35%) control
subjects had persistent elevated IgA antibody, re£ecting
chronic Cpn infection (Table 3).
In 38 COPD patients, 13 (34%) patients were acutely
and 25 (65%) were chronically infected with Cpn
whereas in controls, one (5%) case had acute and six
(35%) cases had chronic Cpn infection (Table 4).TABLE 3. Immunoglobulin prevalence of the subjects
COPD (n= 3
Cpn IgG1: 512 or four-fold rise 13 (34%)
Cpn IgG (1: ^1:256) 25 (65%)
Cpn IgM1:16 12 (31%)
Cpn IgA1:16 12 (31%)
TABLE 4. Type of Cpn infection in the subjects
Acute Cpn Chr
COPD (n= 38) 13 (34%) 2
Control (n= 17) 1 (5%)
Total 14 (25%) 3
TABLE 2. Pulmonary function test and blood gases
parameters of COPD patients
(mean+SD)
FEV1 (% predicted) 33?6+13?4
FVC (% predicted) 42?6+13?4
FEV1/FVC (%) 75+12?3
PaO2 (mmHG) (N=80^100) 47?08+16?7
PaCO2 (mmHG) (N=35^45) 52?06+10?8
pH (N-7?35^7?45) 7?38+0?1
HCO3 (mEql
71) (N=22^24) 24+1?8
O2 saturation (%) (N=96%) 72+7?8
N=normalvalues.Cpn IgG antibody prevalence increased with age
(r=0?3, P50?05). IgM antibody prevalence was posi-
tively correlated with cigarette consumption (r=0?28,
P50?05), but there was no relation between Cpn anti-
body prevalence and gender (P40?05).
Therewas no sign of acute infection forC. psittaci orC.
trachomatis in any subject and the antibody prevalence
for themwere similar in the two groups (P40?05).
Nasopharyngeal swab specimens did not grow any
pathogen bacteria on culturemedia.
Sputa from 23 (60%) COPD patients grew 42 faculta-
tive pathogenic bacteria.The twomost prevalentmicro-
organisms were Gram-positive and -negative cocci (a-
haemolytic streptococci,Niesseria spp.) in15 and13 of 42
isolates (35% and 31%) respectively.Candida ssp. (9?5%),S.
pneumoniae (4?7%), S. aureus (4?7%), P. aeruginosa (4?7%)
andH. in£uenzae (4?7%) were isolated.Number and per-
centage of pathogens are shown inTable 5 and Fig.1.
In 38 COPD patients 13 (34%) were acutely infected
with Cpn. Nine cases were also common bacterial cul-
ture-positive. The four remaining cases were common
culture-negative.Therefore, in only four cases out of 38
(10%),Cpnwas the sole infectious agent (Table 6).
DISCUSSION
Chlamydia pneumoniae infection is characterized by
opportunistic nature intracellular persistence, dissemi-
nation and reactivation.Because of these features it can-
not be cultivated unless using appropriate cell culture
techniques. The presence of Cpn infection in acute and
chronic lung diseases may account for the promotion of
clinical severity and/or poor therapeutic outcomes (1,6).
COPD is a chronic lung disease, which has the major
risk factor from smoking. A intriguing question has been8) Control (n= 17) P value
0 (0%) 50?05
7 (47%) =0?05
1 (5%) 50?01
7 (41%) 40?05
onic Cpn None Total
5 (65%) 0 (0%) 38 (100%)
6 (35%) 10 (59%) 17 (100%)
1 (56%) 10 (18%) 55 (100%)
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with acute exacerbations of COPD (1).
Smoking is quantitatively associated with increased
levels of Cpn serum antibodies in subjects. Possible ex-
planations for these ¢ndings are that smoking facilitates
Cpn lung infection and/or promotes deeper penetration
of Cpn into lung tissue to produce a greater antibody
response. Chronic Cpn infection may facilitate accesses
of di¡erent pathogens to the lower airways, ampli¢es
smoking-associated in£ammation in the bronchi ofFIG. 1. Distribution of pathogens in COPD patients.
TABLE 6. Summaryofthe aetiological agents in exacerbation o
Serology Commonbacterial culture*-posit
Acute Cpn infection () 9 (39%)
Acute Cpn infection (7) 14 (61%)
Total 23 (100%)
*Culture for Cpnwasnotperformed.
TABLE 5. Pathogens isolated from sputa cultures of 23
COPD patients
Pathogens n percent
a-haemolytic streptococci 15 35?7
Niesseria spp. 13 30?9
Candida spp. 4 9?5
S. pneumoniae 2 4?7
S. aureus 2 4?7
P. aeruginosa 2 4?7
H. in£uenza 2 4?7
Undetermined 2 4?7
Total 42 100patientswithCOPD andcontributes to thedevelopment
of irreversible airway obstruction. Moreover, steroids
are prescribed to relieve airway obstruction and this in
turn causes new Cpn infections by a¡ecting themucosal
barrier and humoral immunity (2). By contrast, von
Hertzen et al. showed that smoking did not prove to be
a signi¢cantconfounder of theCpn^COPD infection (3).
In agreement with the former hypotheses, we found a
positive correlation between acute Cpn infection and ci-
garette consumption.
Recent studies have shown the association of Cpn in-
fection in 4^16% of COPD exacerbations of in hospita-
lized or outpatients (2). We have encountered a
considerably high prevalence rate (34%) of acute Cpn
infection in acutelyexacerbatedCOPDpatients.Therea-
son for this is not explained but we think that the
excessive use of steroids for the management of COPD
may cause this result.
Sero-epidemiological studies have shown that older
patients had frequent reinfections with Cpn, while
younger patients had primary infections (11). In the pre-
sent study, most patients with acute Cpn infection had
IgM antibody titre suggesting the reinfection type (with
IgG and/or IgA positivity).
It is shown that persisting Cpn IgG antibodies repre-
senting chronic infection for years after an infection are
frequently found in adult and elderly populationsf COPD
ive Commonbacterial culture*-negative Total
4 (26%) 13 (34%)
11 (73%) 25 (65%)
15 (100%) 38 (100%)
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age, representing previous Cpn infection in all of our
cases asmentioned in the literature.
Cpn antibodies havebeen reported to be higher in the
male population (2,3,5).However, we did not detect any
correlation between gender and antibody prevalence.
In our study, due to the strict inclusion criteria, includ-
ing smokinghistory, for the subjects, the number of con-
trols without COPD remained small, because, when age
and years of smoking history increased, the diagnosis of
COPD became prominent. However, we managed to
study almost similar age groups.We found that COPD
patients had high prevalences of IgG and IgM antibodies.
However, IgG persistant antibody prevalences were
similar between thegroups, showing thatcases at similar
ages have an equal likelihood for previous Cpn infection
in our study population inTurkey.
Documenting persistent Chlamydial infections, cul-
ture or antigen investigations have turned out to be un-
successful. Persistence of elevated serum levels of short-
lived (5 days) IgA antibodies has beenproposed as amar-
ker for a chronic recurrent infection or active carrier
state.Thepersistentlyelevated IgA antibody titres found
during exacerbations suggest the possibility of a continu-
ous or intermittent activation process by Cpn in the
bronchi.The obvious site of infection in the deeper bron-
chial layersmay cause a continuous antigen shedding and
act as a stimulus for IgA production. Due to the short
half-life of IgA antibodies the levels decline rapidly after
acute infection, and thus presence of IgA antibodies dur-
ing interepidemic years may indicate chronic infections
(2,3,5).We detectedelevated levels of IgA levels inpaired
sera of12 (31%) of the COPD patients and seven (41%) of
controls. No signi¢cant di¡erences between the groups
were shown in IgA antibody prevalence.We think that
elevated IgA antibodies should be evaluated together
with other immunoglobulins because it may be inter-
preted as acute and/or chronic Cpn infection as in our
cases.
The rate of seropositivity for Cpn infection has been
reported to bebetween 63% and 87%.The seropositivity
rate of Cpn inTurkey has been previously reported to be
64?3% (12).With regards to our results, in the COPDpo-
pulation, the seropositivity rate for Cpn (65%) is similar
to that of the overall population in European countries.
In European countries, acute Cpn infection rate in
COPD patients with acute exacerbation is in the order
of 4^7?8% (3,4,9,13,14). In such patients, Soler et al. re-
ported18% of acuteCpn infection,whichwas arelatively
high frequency (5). However, acute Cpn infection rate in
COPD (34%) was signi¢cantly and unexpectedly higher
in our study subjects than others.
Recent studies have suggested that Cpn might play a
possible role in childhood asthma (11). It has been shown
that asthma in adults was signi¢cantly associated with
elevated IgG antibody levels against Cpn, and this asso-ciation has been the most important factor for non-
atopic, long-standing asthma (15). It is di⁄cult to clarify
but some of the COPD patients may have been in the
overlapping area in aVenn diagram of asthma and COPD
groups. But it is better to say that our subjects had no
history of asthma symptoms in the past or during adult-
hood.
Investigating the role of the bronchial infection in
acute exacerbations of COPD has yielded con£icting re-
sults. Microbial patterns corresponded to community-
acquiredpathogens (S. pneumoniae,H. in£uenzae andMor-
axella catarrhalis), and to Gram-negative enteric bacteria
in most COPD patients. But the studies on cultivating
sputum mention that the results are vulnerable due to
sampling errors and oral contamination.Other methods
such as serology have been investigated for detection of
the infectious agent (5).Therefore, the present study has
another important aspects from two points of view.
First, serology had a moderately high independent im-
pact on detecting a possible cause for the disease. Sec-
ond, the rate of Gram-positive and -negative cocci (a-
haemolytic streptococci andNiesseria spp.) isolated from
sputawereunexpectedly high,mostprobablydue to oral
contamination.
In conclusion, in a well-selected populationwith acute
purulent exacerbation of COPD, serological studies
showed acute Cpn infection in 34%, and bacteria were
cultured from 28 of 38 patients (60%). Althoughwewere
unable to perform appropriate analyses to verify viral
aetiological agents, and were not able to perform PCR
and/or Cpn cultures, it seems that Cpn is an important
aetiological agent in the exacerbation of COPD.We sug-
gest that,Cpn should be kept in mind in COPD patients
because it may either be the sole causative agent or
frequently a co-agent in acute exacerbations.
REFERENCES
1. Hahn DL. Chlamydia pneumoniae. asthma. and COPD: what is
evidence? Ann Allergy Asthma Immunol1999; 83: 271^292.
2. Mogfl ulkoc° N, Karakurt S, Isalska B, et al. Acute prulent exacerba-
tion of chronic obstructive pulmonary disease andChlamydia pneu-
moniae infection.Am J Respir Crit Care Med1999:160: 349^353.
3. von Hertzen L, Isoaho R, Leinonen M, et al.Chlamydia pneumoniae
antibodies in chronic obstructive pulmonary disease.Int J Epidemiol
1996: 25: 658^664.
4. MiyashitaN,Niki Y,NakajimaM,KawaneH,MatsushimaT. Chlamy-
dia pneumoniae infection in patients with di¡use panbronchiolitis
and COPD.Chest l998; 114: 969^971.
5. Soler N,Torres A, Ewing S, et al.Bronchialmicrobial patterns in se-
vere exacerbations of chronic obstructive pulmonary, disease
(COPD) requiring mechanical ventilation. Am J Respir Crit Care
Med1998; 157:1498^1505.
6. Laurilla AL, von-Hertzen L, Saikku P. Chlamydia pneumoniae and
chronic lung diseases. Scand J Infect Dis1997; 104 (Suppl.): 34^36.
7. AmericanThoracic Society.Lung function selection of reference va-
lues and interpretative strategies. Am Rev Respir Dis 1991; 144:
1202^1218.
816 RESPIRATORYMEDICINE8. Ballows A, WJ Harsler Jr.Manual of Clinical Microbiology (5th Edn).
Washington DC: AmericanSociety forMicrobology,1991; 209^553.
9. Blasi F, Legnani D, Lombard VM. et al. Chlamydia pneumoniae infec-
tion in acute exacerbations of COPD.Eur Respir J1993; 6:19^22.
10. ThomH,Grayston JT,Wang SP,KuoCC, Altmann J.Chlamydia pneu-
moniae and viral infections in acute respiratory disease in a univer-
sity student health clinical population. Am J Epidemiol 1990; 132:
228^256.
11. Miyashita N, KubotaY, Nakajima M,Niki Y, Kawane H, Matsushima
T,Chlamydia pneumoniae and exacerbations of asthma in adults.Ann
Allergy Asthma Immunol1998; 80: 405^409.
12. Gencay M, Dereli D, Ertem E, Serter D, Puolakkainen M, Saikku
Prevalence ofChlamydia pneumoniae speci¢c antibodies in di¡erentclinical situation andhealthy subjects in Izmir,Turkey.Eur J Epidemiol
1998; 14: 505^509.
13. von Hertzen L,T˛yryla M.Gimishanov A, et al. Asthma. atopy and
Chlamydia pneumoniae antibodies in adults.Clin Exp Allergy1998; 29:
522^528.
14. Beaty CD, Grayston JT, Wang SP, Kuo CC, Reto CS, Martin TR.
Chlamydia pneumoniae strain TWAR, infection in patients with
chronic obstructive pulmonarydisease.Am Rev Respir Dis1991; 144:
1408^1410.
15. Cunningham AF, Johnson SL, Julious SA, Lampe FC, Ward ME.
ChronicChlamydia pneumoniae infection and asthma exacerbations
in children.Eur Respir J1998; 11: 345^349.
